Earlier clinical response predicts low rates of radiographic progression in biologic-naïve patients with active psoriatic arthritis receiving guselkumab treatment

被引：0

作者：

Philip J. Mease

Alice B. Gottlieb

Alexis Ogdie

Iain B. McInnes

Soumya D. Chakravarty

Emmanouil Rampakakis

Alexa Kollmeier

Xie L. Xu

May Shawi

Frederic Lavie

Mitsumasa Kishimoto

Proton Rahman

机构：

[1] Swedish Medical Center/Providence St. Joseph Health and University of Washington,Department of Dermatology

[2] Icahn School of Medicine at Mount Sinai,Division of Rheumatology

[3] University of Pennsylvania School of Medicine,College of Medical Veterinary and Life Sciences

[4] University of Glasgow,Department of Pediatrics

[5] Janssen Scientific Affairs,Immunology

[6] LLC,Immunology

[7] Drexel University College of Medicine,Department of Nephrology and Rheumatology

[8] McGill University,Discipline of Medicine, Division of Rheumatology

[9] JSS Medical Research,undefined

[10] Janssen Research & Development,undefined

[11] LLC,undefined

[12] Janssen Research & Development,undefined

[13] LLC,undefined

[14] Janssen Cilag Global Medial Affairs,undefined

[15] Immunology Global Medical Affairs,undefined

[16] Kyorin University School of Medicine,undefined

[17] Memorial University of Newfoundland,undefined

来源：

Clinical Rheumatology | 2024年 / 43卷

关键词：

DAPSA; Guselkumab; Psoriatic arthritis; Radiographic progression; Structural joint damage; vdH-S score;

D O I：

暂无

中图分类号：

学科分类号：

摘要：

引用

页码：241 / 249

页数：8

共 50 条

[21] Effect of subcutaneous tocilizumab treatment on work/housework status in biologic-naïve rheumatoid arthritis patients using inverse probability of treatment weighting: FIRST ACT-SC study
Yoshiya Tanaka
Hideto Kameda
Kazuyoshi Saito
Yuko Kaneko
Eiichi Tanaka
Shinsuke Yasuda
Naoto Tamura
Keishi Fujio
Takao Fujii
Toshihisa Kojima
Tatsuhiko Anzai
Chikuma Hamada
Yoshihisa Fujino
Shinya Matsuda
Hitoshi Kohsaka
Arthritis Research & Therapy, 20
[22] Low Rates of Radiographic Progression with 2 Years of Guselkumab (TREMFYA®), a Selective Inhibitor of the Interleukin-23p19 Subunit: Results from a Phase 3, Randomized, Double-blind, Placebo-controlled Study of Biologic-naive Patients with Active Psoriatic Arthritis
Mease, Philip
Gottlieb, Alice
McInnes, Iain
Rahman, Proton
Kollmeier, Alexa
Xu, Xie
Jiang, Yusang
Sheng, Shihong
Shawi, May
Chakravarty, Soumya
Lavie, Frederic
van der Heijde, Desiree
ARTHRITIS & RHEUMATOLOGY, 2021, 73 : 3763 - 3765
[23] Guselkumab demonstrated an independent treatment effect in reducing fatigue after adjustment for clinical response—results from two phase 3 clinical trials of 1120 patients with active psoriatic arthritis
Proton Rahman
Philip J. Mease
Philip S. Helliwell
Atul Deodhar
Laure Gossec
Arthur Kavanaugh
Alexa P. Kollmeier
Elizabeth C. Hsia
Bei Zhou
Xiwu Lin
May Shawi
Chetan S. Karyekar
Chenglong Han
Arthritis Research & Therapy, 23
[24] Guselkumab demonstrated an independent treatment effect in reducing fatigue after adjustment for clinical response-results from two phase 3 clinical trials of 1120 patients with active psoriatic arthritis
Rahman, Proton
Mease, Philip J.
Helliwell, Philip S.
Deodhar, Atul
Gossec, Laure
Kavanaugh, Arthur
Kollmeier, Alexa P.
Hsia, Elizabeth C.
Zhou, Bei
Lin, Xiwu
Shawi, May
Karyekar, Chetan S.
Han, Chenglong
ARTHRITIS RESEARCH & THERAPY, 2021, 23 (01)
[25] Low rates of radiographic progression of structural joint damage over 2 years of baricitinib treatment in patients with rheumatoid arthritis
van Der Heijde, Desiree
Schiff, Michael
Tanaka, Yoshiya
Xie, Li
Meszaros, Gabriella
Ishii, Taeko
Casillas, Marta
Ortmann, Robert A.
Emery, Paul
RMD OPEN, 2019, 5 (01):
[26] LOW RATES OF RADIOGRAPHIC PROGRESSION OF STRUCTURAL JOINT DAMAGE OVER 2 YEARS OF BARICITINIB TREATMENT IN PATIENTS WITH RHEUMATOID ARTHRITIS
van der Heijde, D.
Schiff, M.
Tanaka, Y.
Klar, R.
Xie, L.
Meszaros, G.
Ishii, T.
Casillas, M.
Ortmann, R.
Emery, P.
ANNALS OF THE RHEUMATIC DISEASES, 2017, 76 : 510 - 511
[27] Active synovitis in the presence of osteitis predicts residual synovitis in patients with rheumatoid arthritis with a clinical response to treatment
Fukae, Jun
Tanimura, Kazuhide
Isobe, Masato
Kitano, Akemi
Henmi, Mihoko
Nakai, Maria
Aoki, Yuko
Sakamoto, Fumihiko
Narita, Akihiro
Ito, Takeya
Mitsuzaki, Akio
Matsuhashi, Megumi
Shimizu, Masato
Kamishima, Tamotsu
Atsumi, Tatsuya
Koike, Takao
INTERNATIONAL JOURNAL OF RHEUMATIC DISEASES, 2018, 21 (10) : 1809 - 1814
[28] Achievement of Very Low Disease Activity and Remission Treatment Targets Is Associated with Reduced Radiographic Progression in Patients with Psoriatic Arthritis Treated with Certolizumab Pegol
Coates, Laura
Merola, Joseph
Kavanaugh, Arthur
Mease, Philip
Davies, Owen
Irvin-Sellers, Oscar
Nurminen, Tommi
van der Heijde, Desiree
ARTHRITIS & RHEUMATOLOGY, 2019, 71
[29] ACHIEVEMENT OF VERY LOW DISEASE ACTIVITY AND REMISSION TREATMENT TARGETS IS ASSOCIATED WITH REDUCED RADIOGRAPHIC PROGRESSION IN PATIENTS WITH PSORIATIC ARTHRITIS TREATED WITH CERTOLIZUMAB PEGOL
Coates, L. C.
Merola, J. F.
Kavanaugh, A.
Mease, P. J.
Davies, O.
Irvin-Sellers, O.
Nurminen, T.
Van der Heijde, D.
ANNALS OF THE RHEUMATIC DISEASES, 2020, 79 : 754 - 755
[30] Bimekizumab treatment in biologic DMARD-na & iuml;ve patients with active psoriatic arthritis: 52-week efficacy and safety results from the phase III, randomised, placebo-controlled, active reference BE OPTIMAL study
Ritchlin, Christopher T.
Coates, Laura C.
Mcinnes, Iain B.
Mease, Philip J.
Merola, Joseph F.
Tanaka, Yoshiya
Asahina, Akihiko
Gossec, Laure
Gottlieb, Alice B.
Warren, Richard B.
Ink, Barbara
Bajracharya, Rajan
Shende, Vishvesh
Coarse, Jason
Landewe, Robert B. M.
ANNALS OF THE RHEUMATIC DISEASES, 2023, 82 (11) : 1404 - 1414

← 1 2 3 4 5 →